Skip to main content
ARTIVION, INC. logo

ARTIVION, INC. — Investor Relations & Filings

Ticker · AORT ISIN · US2289031005 LEI · 549300YTKV8DMSMG6K81 US Manufacturing
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2021-11-05 Director's Dealing
Country US United States of America
Listing US AORT

About ARTIVION, INC.

https://artivion.com/

Artivion, Inc. is a medical device company focused on developing, manufacturing, and distributing solutions for cardiac and vascular surgery. The company has an intentional focus on creating technologies to treat diseases of the aorta. In collaboration with surgeons, Artivion develops products designed to address complex surgical challenges. Its portfolio includes a range of aortic-centric technologies, such as heart valve solutions, implantable human tissues (allografts), surgical sealants, and various stent grafts for the aortic arch, thoracoabdominal, abdominal, and peripheral aorta. The company's purpose is to provide simple, elegant solutions that improve surgical outcomes for patients with aortic diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-11-05 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its financial results for the quarter ended September 30, 2021, and that the press release is attached as Exhibit 99.1. The document states that the information is "furnished" pursuant to Item 2.02 of Form 8-K and is not "filed" for certain legal purposes. The content is primarily an announcement of quarterly financial results via a press release, not the full financial report itself. The document length is about 5257 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2021-11-04 English
PRIMARY DOCUMENT
Director's Dealing
2021-10-08 English
ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS' and references Schedule 14A, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about a special stockholder meeting, voting instructions, and proposals to be voted on, such as reincorporation and approval of corporate governance provisions. The content is focused on soliciting shareholder votes and providing proxy materials rather than presenting financial results or management discussion. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is over 5,000 characters and contains substantive proxy material, not just an announcement or notice, so it is not an RPA or RNS.
2021-10-07 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2021-10-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.